Presentation
7 March 2022 Multiplexing drug-target engagement and metabolic imaging in HER2-positive tumor xenograft models
Author Affiliations +
Abstract
Macroscopic fluorescence lifetime FRET imaging (MFLI-FRET) presents a much-needed analytical tool to non-invasively quantify drug-receptor engagement in tumors and other organs in preclinical studies. We demonstrate the specificity and sensitivity of MFLI-FRET for direct and robust measurement of trastuzumab-HER2 target engagement in various types of breast and ovarian cancer tumor xenograft models. Simultaneous metabolic imaging with IRDye 800 CW 2-DG reveals that intracellular delivery of drug is associated with 2-DG lifetime and likely reflects tumors’ microenvironment and perfusion state.
Conference Presentation
© (2022) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Alena Rudkouskaya, Jason T. Smith, Xavier R. Intes, and Margarida Barroso "Multiplexing drug-target engagement and metabolic imaging in HER2-positive tumor xenograft models", Proc. SPIE PC11938, Visualizing and Quantifying Drug Distribution in Tissue VI, PC1193809 (7 March 2022); https://doi.org/10.1117/12.2607308
Advertisement
Advertisement
KEYWORDS
Tumors

Fluorescence resonance energy transfer

Multiplexing

Tumor growth modeling

Luminescence

Signal detection

Systems modeling

Back to Top